Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Topline Phase 2 Results from Ongoing LPCN 1144 Lift Study in Biopsy-Confirmed Nash Subjects
 Tuesday, January 12, 2021
 8:30am EST